

markets) of Washington apricots was approximately 6,700 tons, the average price was \$1,250 per ton, and the total farm-gate value was approximately \$8,371,000. Based on these reports and the number of apricot growers within the production area, it is estimated that the 2012 average revenue from the sale of apricots was approximately \$89,000. In addition, based on information from the USDA's Market News Service, 2012 f.o.b. prices for WA No. 1 apricots ranged from \$16.00 to \$24.00 per 24-pound loose-pack container, and from \$18.00 to \$27.00 for 2-layer tray-pack containers. Using average price and shipment information provided by the Committee, it is determined that each of the Washington apricot handlers currently ship less than \$7,000,000 worth of apricots on an annual basis. In view of the foregoing, it is concluded that the majority of growers and handlers of Washington apricots may be classified as small entities.

This rule continues in effect the action that suspended the handling regulations specified in §§ 922.111 and 922.321 for the remainder of the 2013–2014 fiscal period and subsequent fiscal periods. The suspension of these handling regulations allows the Washington apricot industry to market apricots without regard to the minimum grade, size, quality, maturity, and inspection requirements prescribed under the order. Authority for this action is provided in § 922.53.

This action is not expected to increase the costs associated with the order requirements. Rather, this action allows handlers to decrease their costs during the 2013–2014 fiscal period and subsequent fiscal periods by eliminating the expense associated with mandatory inspection. However, this rule does not impede handlers from seeking inspection on a voluntary basis if they find inspection desirable. The opportunities and benefits of this rule are equally available to all Washington apricot handlers and producers, regardless of their size.

In accordance with the Paperwork Reduction Act of 1995, (44 U.S.C. Chapter 35), the order's information collection requirements have been previously approved by the Office of Management and Budget (OMB) and assigned OMB No. 0581–0189. No

changes in those requirements as a result of this action are necessary. Should any changes become necessary, they would be submitted to OMB for approval.

This rule will not impose any additional reporting or recordkeeping requirements on either small or large apricot handlers. As with all Federal marketing order programs, reports and forms are periodically reviewed to reduce information requirements and duplication by industry and public sector agencies. In addition, USDA has not identified any relevant Federal rules that duplicate, overlap or conflict with this rule.

Further, the Committee's meeting was widely publicized throughout the Washington apricot industry and all interested persons were invited to attend the meeting and participate in the Committee's deliberations. Like all Committee meetings, the May 13, 2013, meeting was a public meeting. All entities, both large and small, were able to express their views on this issue.

Comments on the interim rule were required to be received on or before December 23, 2013. No comments were received. Therefore, for the reasons given in the interim rule, we are adopting the interim rule as a final rule, without change.

To view the interim rule, go to: <http://www.regulations.gov/#!documentDetail;D=AMS-FV-13-0040-0001>.

This action also affirms information contained in the interim rule concerning Executive Orders 12866, 12988, and 13563; the Paperwork Reduction Act (44 U.S.C. Chapter 35); and the E-Gov Act (44 U.S.C. 101), as well as the findings in the interim rule that the regulatory requirements no longer tend to effectuate the declared policy of the Act.

After consideration of all relevant material presented, it is found that finalizing the interim rule, without change, as published in the **Federal Register** (78 FR 62963, October 23, 2013) will tend to effectuate the declared policy of the Act.

**List of Subjects in 7 CFR Part 922**

Apricots, Marketing agreements, Reporting and recordkeeping requirements.

**PART 922—[AMENDED]**

■ Accordingly, the interim rule that amended 7 CFR part 922 and was published at 78 FR 62963 on October 23, 2013, is adopted as a final rule, without change.

Dated: February 26, 2014.

**Rex A. Barnes,**

*Associate Administrator, Agricultural Marketing Service.*

[FR Doc. 2014–06084 Filed 3–19–14; 8:45 am]

**BILLING CODE 3410–02–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Part 558**

[Docket No. FDA–2014–N–0002]

**Withdrawal of Approval of New Animal Drug Applications; Chlortetracycline; Sulfathiazole; Penicillin**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notification of withdrawal of approval.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing approval of a new animal drug application (NADA) and two abbreviated new animal drug applications (ANADAs) for three-way, fixed-ratio combination drug Type A medicated articles containing chlortetracycline, sulfathiazole, and penicillin. This action is being taken at the sponsor's request because these products are no longer manufactured or marketed.

**DATES:** Withdrawal of approval is effective March 31, 2014.

**FOR FURTHER INFORMATION CONTACT:** David Alterman, Center for Veterinary Medicine (HFV–212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–453–6843.

**SUPPLEMENTARY INFORMATION:** Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 has requested that FDA withdraw approval of the following NADA and two ANADAs because the products are no longer manufactured or marketed:

NADA/ANADA	Proprietary name
039–077 .....	CSP 250 (chlortetracycline, sulfathiazole, and penicillin) Type A medicated article.
200–140 .....	AUREOZOL (chlortetracycline, sulfathiazole, and penicillin) Type A medicated article.
200–167 .....	AUREOZOL 500 Granular (chlortetracycline, sulfathiazole, and penicillin) Type A medicated article.

The NADAs listed were identified as being affected by guidance for industry (GFI) #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209”, December 2013.

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 *Notice of withdrawal of approval of application* (21 CFR 514.116), notice is given that approval of NADA 039–077, ANADA 200–140, and ANADA 200–167, and all supplements and amendments thereto, is hereby withdrawn, effective March 31, 2014.

Elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to reflect the voluntary withdrawal of approval of these applications.

Dated: March 12, 2014.  
**Bernadette Dunham**,  
*Director, Center for Veterinary Medicine.*  
 [FR Doc. 2014–05883 Filed 3–19–14; 8:45 am]  
**BILLING CODE 4160–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Part 558**

[Docket No. FDA–2014–N–0002]

**Zoetis Inc., Withdrawal of Approval of New Animal Drug Applications; Chlortetracycline; Sulfathiazole; Penicillin**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the withdrawal of approval of a new animal

drug application (NADA) and two abbreviated new animal drug applications (ANADAs) for three-way, fixed-ratio combination drug Type A medicated articles containing chlortetracycline, sulfathiazole, and penicillin. This action is being taken at the sponsor’s request because these products are no longer manufactured or marketed.

**DATES:** This rule is effective March 31, 2014.

**FOR FURTHER INFORMATION CONTACT:** David Alterman, Center for Veterinary Medicine (HFV–212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–453–6843.

**SUPPLEMENTARY INFORMATION:** Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 has requested that FDA withdraw approval of the following NADA and two ANADAs because the products are no longer manufactured or marketed:

NADA/ANADA	Proprietary name
039–077 .....	CSP 250 (chlortetracycline, sulfathiazole, and penicillin) Type A medicated article.
200–140 .....	AUREOZOL (chlortetracycline, sulfathiazole, and penicillin) Type A medicated article.
200–167 .....	AUREOZOL 500 Granular (chlortetracycline, sulfathiazole, and penicillin) Type A medicated article.

The NADAs listed were identified as being affected by guidance for industry (GFI) #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209”, December 2013.

Elsewhere in this issue of the **Federal Register**, FDA gave notice that approval of NADA 039–077, ANADA 200–140, and ANADA 200–167, and all supplements and amendments thereto, is withdrawn, effective March 31, 2014. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these voluntary withdrawals of approval.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

**List of Subjects in 21 CFR Part 558**

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner

of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

**PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS**

■ 1. The authority citation for 21 CFR part 558 continues to read as follows:

**Authority:** 21 U.S.C. 360b, 371.

**§ 558.4 [Amended]**

■ 2. In § 558.4(d), in the “Category II” table, remove the entry for “Sulfathiazole” and its respective following entries.

**§ 558.155 [Removed]**

■ 3. Remove § 558.155.

Dated: March 12, 2014.  
**Bernadette Dunham**,  
*Director, Center for Veterinary Medicine.*  
 [FR Doc. 2014–05882 Filed 3–19–14; 8:45 am]  
**BILLING CODE 4160–01–P**

**DEPARTMENT OF VETERANS AFFAIRS**

**38 CFR Part 17**

RIN 2900–AO85

**VA Dental Insurance Program—Federalism**

**AGENCY:** Department of Veterans Affairs.  
**ACTION:** Direct final rule; confirmation of effective date.

**SUMMARY:** The Department of Veterans Affairs (VA) published a direct final rule in the **Federal Register** on October 22, 2013, amending its regulations related to the VA Dental Insurance Program (VADIP), a pilot program to offer premium-based dental insurance to enrolled veterans and certain survivors and dependents of veterans. Specifically, this rule adds language to clarify the limited preemptive effect of certain criteria in the VADIP regulations. VA received no comments concerning this rule or its companion substantially identical proposed rule published in the **Federal Register** on October 23, 2013. This document confirms that the direct final rule became effective on December 23, 2013. In a companion document in this issue